What's new? Log in Free sign up

BioNTech SE (BNTX)

Company Profile

Company profile

Ticker

BNTX

Exchange

Website

www.biontech.de

CEO

Dr. Ugur Sahin M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment ...

Former names

Ethereum Investment Trust, Grayscale Ethereum Trust (ETH)

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

BNTX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$171.00

Low target

$170.00

High target

$172.00

Truist Securities

Latest filings (excl ownership)

View all

Current report (foreign)

BioNTech Completes Acquisition of Biotheus

BioNTech provides business and pipeline updates at 43rd annual J.P. Morgan Healthcare Conference

Current report (foreign)

Current report (foreign)

Current report (foreign)

1 Welcome & Introductory Remarks Ryan Richardson, Chief Strategy Officer

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Current report (foreign)

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart BNTX financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from BioNTech SE earnings reports.

Institutional ownership, Q4 2024

BNTX institutional ownership history Ownership history

81.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	304	300	+1.3%
Opened positions	64	77	-16.9%
Closed positions	60	64	-6.3%
Increased positions	81	74	+9.5%
Reduced positions	85	93	-8.6%

13F shares	Current	Prev Q	Change
Total value	5.64 tn	5.08 tn	+10.9%
Total shares	194.37 mm	187.85 mm	+3.5%
Total puts	1.99 mm	2.29 mm	-12.7%
Total calls	2.78 mm	2.45 mm	+13.7%
Total put/call ratio	0.7	0.9	-23.2%

Largest owners	Shares	Value	Change
Athos KG	102.49 mm	$11.68 bn	0.0%
Medine GmbH	40.44 mm	$0.00	0.0%
Baillie Gifford & Co	8.22 mm	$936.74 bn	-1.1%
FMR	7.70 mm	$877.58 bn	+22.2%
Flossbach Von Storch	4.41 mm	$502.16 bn	+1.1%
Primecap Management	4.30 mm	$489.51 bn	-4.9%
PFE Pfizer	3.66 mm	$416.87 bn	NEW
BlackRock	1.86 mm	$211.54 bn	-10.4%
Temasek	1.81 mm	$205.93 bn	0.0%
Capital International Investors	1.42 mm	$161.30 bn	+38.6%

Largest transactions	Shares	Bought/sold	Change
PFE Pfizer	3.66 mm	+3.66 mm	NEW
FMR	7.70 mm	+1.40 mm	+22.2%
Viking Global Investors	940.85 k	+894.56 k	+1932.3%
Balyasny Asset Management	0.00	-620.47 k	EXIT
BNP Paribas Arbitrage	614.30 k	+614.30 k	NEW
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	501.90 k	+433.39 k	+632.6%
UBS UBS	529.05 k	+406.07 k	+330.2%
Capital International Investors	1.42 mm	+394.43 k	+38.6%
Point72 Asset Management	0.00	-361.99 k	EXIT
Logos Global Management	300.00 k	+300.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Nasdaq Falls Into Correction As Tariffs Roil Wall Street: What's Moving Markets Friday?

All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024.

'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News

CDC study follows measles outbreak amid declining vaccination ratesKennedy's mixed messages on vaccines raise concernsAutism rise attributed to broader screening, not vaccinesMarch 7 - The U.S. Centers for Disease

BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine

'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail

Press releases

From Benzinga Pro

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025.

BioNTech Completes Acquisition of Biotheus

Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transaction, BioNTech will

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.